+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pancreatic Cancer Drugs Global Market Opportunities and Strategies to 2032

  • PDF Icon

    Report

  • 295 Pages
  • April 2023
  • Region: Global
  • The Business Research Company
  • ID: 5783592
This report describes and explains the pancreatic cancer drugs market and covers 2017-2022, termed the historic period, and 2022-2027 termed the forecast period, along with further forecasts for the period 2027-2032. The report evaluates the market across each region and for the major economies within each region.

The global pancreatic cancer drugs market reached a value of nearly $3,872.5 million in 2022, having increased at a compound annual growth rate (CAGR) of 6.5% since 2017. The market is expected to grow from $3,872.5 million in 2022 to $5,519.4 million in 2027 at a rate of 7.3%. The market is then expected to grow at a CAGR of 6.9% from 2027 and reach $7,720.1 million in 2032.

Growth in the historic period resulted from strong economic growth in emerging markets, an increasing aging population and an increasing prevalence of pancreatic cancer. Factors that negatively affected growth in the historic period were the high cost of drugs, low healthcare access in developing countries and the coronavirus pandemic.

Going forward, an increase in cancer incidence rates, a rise in healthcare expenditure and increasing government support will drive the market. Factors that could hinder the growth of the pancreatic cancer drugs market in the future include a rise in interest rates and the Russia- Ukraine war.

The pancreatic cancer drugs market is segmented by type into pancreatic neuroendocrine cancer drugs and pancreatic exocrine cancer drugs. The pancreatic neuroendocrine cancer drugs was the largest segment of the pancreatic cancer drugs market by type, accounting for $3,698.9 million or 95.5% of the total market in 2022. The pancreatic exocrine cancer drugs market is expected to be the fastest-growing segment going forward at a CAGR of 7.7%.

The pancreatic cancer drugs market is segmented by end-users into hospital pharmacies, retail pharmacies and other end-users. The hospital pharmacies market was the largest segment of the pancreatic cancer drugs market by end-users, accounting for $1,955.9 million or 50.5% of the total market in 2022. The retail pharmacies market is expected to be the fastest-growing segment going forward at a CAGR of 7.5%.

The pancreatic cancer drugs market is segmented by drug combination into single, double, triplet and quadruplet. The double was the largest segment of the pancreatic cancer drugs market by drug combination, accounting for $2,457.6 million or 63.5% of the total market in 2022. It is expected to be the fastest-growing segment going forward at a CAGR of 7.8%.

North America was the largest region in the pancreatic cancer drugs market, accounting for 40.7% of the global market in 2022. It was followed by Western Europe, Asia Pacific and the other regions. Going forward, the fastest growing regions in the pancreatic cancer drugs market will be the Middle East and South America, where growth will be at CAGRs of 13.5% and 10.8% respectively from 2022-2027.

The global pancreatic cancer drugs market is concentrated, with a large number of small players. The top ten competitors in the market made up to 61.17% of the total market in 2021. Bristol-Myers Squibb Company was the largest competitor with 11.94% share of the market, followed by Pfizer Inc. with 10.69%, AstraZeneca PLC with 10.17%, F. Hoffmann-La Roche AG with 9.07%, Novartis AG with 7.20%, Abbvie Inc. with 5.16%, Merck & Co., Inc. with 2.86%, Teva Pharmaceutical Industries with 2.00%, Amgen Incorporation with 1.42% and Eli Lilly and Company with 0.67%.

The top opportunities in the pancreatic cancer drugs market by type will arise in the pancreatic neuroendocrine cancer drugs market, which will gain $1,568.8 million of global annual sales by 2027. The top growth potential in the pancreatic cancer drugs market by end-users will arise in the hospital pharmacies market, which will gain $812.5 million of global annual sales by 2027. The top growth potential in the pancreatic cancer drugs market by drug combination will arise in the double market, which will gain $1,121.4 million of global annual sales by 2027. The pancreatic cancer drugs market size will gain the most in the USA at $461.5 million.

Market-trend-based strategies for the pancreatic cancer drugs market include focus on developing new drugs to treat pancreatic cancer, focus on novel nanomedicine treatment, focus on increasing investments, focus on strategic collaborations and focus on product innovations.

Player-adopted strategies in the pancreatic cancer drugs industry include enhancing business capabilities through strategic partnership and collaborations, focusing on providing targeted treatment options for pancreatic cancer patients through receiving regulatory approvals, strengthening business capabilities through partnerships and collaborations and enhancing business operations through securing regulatory approvals.

To take advantage of the opportunities, the publisher recommends the pancreatic cancer drugs companies to focus on development of new drugs to treat pancreatic cancer, focus on novel nanomedicine treatment for pancreatic cancer treatment, focus on product innovations, expand in emerging markets, continue to focus on developed markets, focus on strategic collaborations, provide competitively priced offerings, continue to use b2b promotions, participate in trade shows and events, continue to target fast-growing end-users.


Table of Contents

1. Executive Summary2. Table Of Contents3. List Of Figures4. List Of Tables5. Report Structure
6. Introduction And Market Characteristics
6.1. General Market Definition
6.2. Summary
6.3. Pancreatic Cancer Drugs Market Definition And Segmentations
6.4. Market Segmentation By Type
6.4.1. Pancreatic Neuroendocrine Cancer Drugs
6.4.2. Pancreatic Exocrine Cancer Drugs
6.5. Market Segmentation By End-User
6.5.1. Hospital Pharmacies
6.5.2. Retail Pharmacies
6.5.3. Other End-Users
6.6. Market Segmentation By Drug Combination
6.6.1. Single
6.6.2. Double
6.6.3. Triplet
6.6.4. Quadruplet
7. Major Market Trends
7.1. Development Of New Drugs To Treat Pancreatic Cancer
7.2. Rising Focus On Novel Nanomedicine Treatment For Pancreatic Cancer Treatment
7.3. Increasing Investments
7.4. Strategic Collaborations
7.5. Product Innovations
8. Global Market Size and Growth
8.1. Market Size
8.2. Historic Market Growth, 2017 - 2022, Value ($ Million)
8.2.1. Market Drivers 2017 - 2021
8.2.2. Market Restraints 2017 - 2022
8.3. Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
8.3.1. Market Drivers 2022 - 2027
8.3.2. Market Restraints 2022 - 2027
9. Global Pancreatic Cancer Drugs Market Segmentation
9.1. Global Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
9.2. Global Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
9.3. Global Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
10. Pancreatic Cancer Drugs Market, Regional and Country Analysis
10.1. Global Pancreatic Cancer Drugs Market, By Region, Historic and Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
10.2. Global Pancreatic Cancer Drugs Market, By Country, Historic and Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11. Asia-Pacific Market
11.1. Summary
11.2. Market Overview
11.2.1. Region Information
11.2.2. Market Information
11.2.3. Background Information
11.2.4. Government Initiatives
11.2.5. Regulations
11.2.6. Regulatory Bodies
11.2.7. Major Associations
11.2.8. Taxes Levied
11.2.9. Corporate Tax Structure
11.2.10. Investments
11.2.11. Major Companies
11.3. Asia-Pacific Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
11.4. Asia-Pacific Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
11.5. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.6. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.7. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.8. Asia-Pacific Pancreatic Cancer Drugs Market: Country Analysis
11.9. China Market
11.10. Summary
11.11. Market Overview
11.11.1. Country Information
11.11.2. Market Information
11.11.3. Background Information
11.11.4. Government Initiatives
11.11.5. Regulations
11.11.6. Regulatory Bodies
11.11.7. Major Associations
11.11.8. Taxes Levied
11.11.9. Corporate Tax Structure
11.11.10. Investments
11.11.11. Major Companies
11.12. China Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
11.13. China Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
11.14. China Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.15. China Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.16. China Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.17. India Market
11.18. India Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
11.19. India Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
11.20. India Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.21. India Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.22. India Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.23. Japan Market
11.24. Japan Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
11.25. Japan Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
11.26. Japan Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.27. Japan Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.28. Japan Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.29. Australia Market
11.30. Australia Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
11.31. Australia Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
11.32. Australia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.33. Australia Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.34. Australia Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.35. Indonesia Market
11.36. Indonesia Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
11.37. Indonesia Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
11.38. Indonesia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.39. Indonesia Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.40. Indonesia Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.41. South Korea Market
11.42. South Korea Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
11.43. South Korea Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
11.44. South Korea Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.45. South Korea Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
11.46. South Korea Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
12. Western Europe Market
12.1. Summary
12.2. Market Overview
12.2.1. Region Information
12.2.2. Market Information
12.2.3. Background Information
12.2.4. Government Initiatives
12.2.5. Regulations
12.2.6. Regulatory Bodies
12.2.7. Major Associations
12.2.8. Taxes Levied
12.2.9. Corporate Tax Structure
12.2.10. Investments
12.2.11. Major Companies
12.3. Western Europe Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
12.4. Western Europe Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
12.5. Western Europe Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
12.6. Western Europe Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
12.7. Western Europe Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
12.8. Western Europe Pancreatic Cancer Drugs Market: Country Analysis
12.9. UK Market
12.10. UK Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
12.11. UK Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
12.12. UK Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
12.13. UK Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
12.14. UK Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
12.15. Germany Market
12.16. Germany Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
12.17. Germany Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
12.18. Germany Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
12.19. Germany Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
12.20. Germany Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
12.21. France Market
12.22. France Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
12.23. France Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
12.24. France Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
12.25. France Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
12.26. France Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
13. Eastern Europe Market
13.1. Summary
13.2. Market Overview
13.2.1. Region Information
13.2.2. Market Information
13.2.3. Background Information
13.2.4. Government Initiatives
13.2.5. Regulations
13.2.6. Regulatory Bodies
13.2.7. Major Associations
13.2.8. Taxes Levied
13.2.9. Corporate Tax Structure
13.2.10. Investments
13.2.11. Major Companies
13.3. Eastern Europe Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
13.4. Eastern Europe Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
13.5. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
13.6. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
13.7. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
13.8. Eastern Europe Pancreatic Cancer Drugs Market: Country Analysis
13.9. Russia Market
13.10. Russia Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
13.11. Russia Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
13.12. Russia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
13.13. Russia Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
13.14. Russia Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
14. North America Market
14.1. Summary
14.2. Market Overview
14.2.1. Region Information
14.2.2. Market Information
14.2.3. Background Information
14.2.4. Government Initiatives
14.2.5. Regulations
14.2.6. Regulatory Bodies
14.2.7. Major Associations
14.2.8. Taxes Levied
14.2.9. Corporate Tax Structure
14.2.10. Investments
14.2.11. Major Companies
14.3. North America Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
14.4. North America Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
14.5. North America Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
14.6. North America Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
14.7. North America Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
14.8. North America Pancreatic Cancer Drugs Market: Country Analysis
14.9. USA Market
14.10. Summary
14.11. Market Overview
14.11.1. Country Information
14.11.2. Market Information
14.11.3. Background Information
14.11.4. Government Initiatives
14.11.5. Regulations
14.11.6. Regulatory Bodies
14.11.7. Major Associations
14.11.8. Taxes Levied
14.11.9. Corporate Tax Structure
14.11.10. Investments
14.11.11. Major Companies
14.12. USA Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
14.13. USA Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
14.14. USA Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
14.15. USA Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
14.16. USA Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
15. South America Market
15.1. Summary
15.2. Market Overview
15.2.1. Region Information
15.2.2. Market Information
15.2.3. Background Information
15.2.4. Government Initiatives
15.2.5. Regulations
15.2.6. Regulatory Bodies
15.2.7. Major Associations
15.2.8. Taxes Levied
15.2.9. Corporate Tax Structure
15.2.10. Investments
15.2.11. Major Companies
15.3. South America Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
15.4. South America Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
15.5. South America Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
15.6. South America Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
15.7. South America Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
15.8. South America Pancreatic Cancer Drugs Market: Country Analysis
15.9. Brazil Market
15.10. Brazil Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
15.11. Brazil Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
15.12. Brazil Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
15.13. Brazil Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
15.14. Brazil Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
16. Middle East Market
16.1. Summary
16.2. Market Overview
16.2.1. Region Information
16.2.2. Market Information
16.2.3. Background Information
16.2.4. Government Initiatives
16.2.5. Regulations
16.2.6. Regulatory Bodies
16.2.7. Major Associations
16.2.8. Taxes Levied
16.2.9. Corporate Tax Structure
16.2.10. Investments
16.2.11. Major Companies
16.3. Middle East Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
16.4. Middle East Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
16.5. Middle East Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
16.6. Middle East Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
16.7. Middle East Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
17. Africa Market
17.1. Summary
17.2. Market Overview
17.2.1. Region Information
17.2.2. Market Information
17.2.3. Background Information
17.2.4. Government Initiatives
17.2.5. Regulations
17.2.6. Regulatory Bodies
17.2.7. Major Associations
17.2.8. Taxes Levied
17.2.9. Corporate Tax Structure
17.2.10. Investments
17.2.11. Major Companies
17.3. Africa Pancreatic Cancer Drugs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
17.4. Africa Pancreatic Cancer Drugs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
17.5. Africa Pancreatic Cancer Drugs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
17.6. Africa Pancreatic Cancer Drugs Market, Segmentation By End-User, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
17.7. Africa Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
18. Competitive Landscape and Company Profiles
18.1. Company Profiles
18.2. Bristol-Myers Squibb Company
18.2.1. Company Overview
18.2.2. Products And Services
18.2.3. Financial Overview
18.3. Pfizer Inc.
18.3.1. Company Overview
18.3.2. Products And Services
18.3.3. Business Strategy
18.3.4. Financial Overview
18.4. AstraZeneca PLC
18.4.1. Company Overview
18.4.2. Products And Services
18.4.3. Business Strategy
18.4.4. Financial Overview
18.5. F. Hoffmann-La Roche AG
18.5.1. Company Overview
18.5.2. Products And Services
18.5.3. Business Strategy
18.5.4. Financial Overview
18.6. Novartis AG
18.6.1. Company Overview
18.6.2. Products And Services
18.6.3. Business Strategy
18.6.4. Financial Overview
19. Pipeline Analysis
20. Key Mergers And Acquisitions
20.1. Leap Therapeutics, Inc. Acquired Flame Biosciences, Inc.
20.2. AstraZeneca Acquired Neogene Therapeutics, Inc.
20.3. Ipsen Acquired Epizyme
20.4. Panbela Therapeutics, Inc. Acquired Cancer Prevention Pharmaceuticals, Inc. (CPP)
20.5. Servier Acquired Agios Pharmaceuticals
20.6. Boehringer Ingelheim Acquired Northern Biologics
21. Opportunities And Strategies
21.1. Global Pancreatic Cancer Drugs Market In 2027 - Countries Offering Most New Opportunities
21.2. Global Pancreatic Cancer Drugs Market In 2027 - Segments Offering Most New Opportunities
21.3. Global Pancreatic Cancer Drugs Market In 2027 - Growth Strategies
21.3.1. Market Trend Based Strategies
21.3.2. Competitor Strategies
22. Pancreatic Cancer Drugs Market, Conclusions And Recommendations
22.1. Conclusions
22.2. Recommendations
22.2.1. Product
22.2.2. Place
22.2.3. Price
22.2.4. Promotion
22.2.5. People
23. Appendix
23.1. Market Data Sources
23.2. Research Methodology
23.3. Currencies
23.4. About the Publisher
23.5. Copyright and Disclaimer

Executive Summary

Pancreatic Cancer Drugs Global Market Opportunities and Strategies to 2032 provides the strategists; marketers and senior management with the critical information they need to assess the global Pancreatic cancer drugs market as it emerges from the COVID 19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Description:

Where is the largest and fastest-growing market for pancreatic cancer drugs? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The Pancreatic cancer drugs market global report answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider pancreatic cancer drugs market; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics
Brief introduction to the segmentations covered in the market, definitions and explanations about pancreatic cancer drugs market.
  • Key Trends
Highlights the major trends shaping the global pancreatic cancer drugs market. This section also highlights likely future developments in the market.
  • Global Market Type and Growth
Global historic (2017-2022) and forecast (2022-2027), and (2027-2032) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional Analysis
Historic (2017-2022) and forecast (2022-2027), and (2027-2032) market values and growth and market share comparison by region.
  • Market Segmentation
Contains the market values (2017-2032) and analysis for segment by drug combination, by type and by end-user in the market.
  • Regional Market Type and Growth
Regional market type (2022), historic (2017-2022) and forecast (2022-2027), and (2027-2032) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape
Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Key Mergers and Acquisitions
Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years
  • Opportunities and Strategies -
This section gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
  • Conclusions and Recommendations -
This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for pancreatic cancer drugs companies in terms of product offerings, geographic expansion, price offerings, and target groups.
  • Appendix -
This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope

Markets Covered:

1) By Type: Pancreatic Neuroendocrine Cancer Drugs; Pancreatic Exocrine Cancer Drugs
2) By Drug Combination: Single; Double; Triplet; Quadruplet
3) By End User: Hospital Pharmacies; Retail Pharmacies; Other End-Users

Companies Mentioned: Bristol-Myers Squibb Company; Pfizer Inc.; AstraZeneca PLC; F. Hoffmann-La Roche AG; Novartis AG

Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time-series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; pancreatic cancer drugs indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche AG
  • Novartis AG

Methodology

Loading
LOADING...

Table Information